+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are studying the physical impact of Multiple Sclerosis MS from the patients perspective while providing continued access to the drug ocrelizumab. This extension study evaluates the safety and tolerability of ocrelizumab in patients previously enrolled in certain parent studies who no longer have local access to the treatment. The study is open-label and multicenter, sponsored by Hoffmann-La Roche. Participants will receive ocrelizumab at approved doses of either 600 mg via intravenous infusion or 920 mg via subcutaneous injection, following the schedule from their original parent study. Treatment will continue until the medication becomes locally available, an unacceptable safety concern arises, the participant dies, or withdraws consent. During the study, participants will be monitored for changes in physical function using patient-reported outcome measures over up to five years. Researchers will also track access to ocrelizumab, serious adverse events, adverse events leading to discontinuation, and adverse events of special interest. The study will last up to five years, with ongoing safety and tolerability assessments throughout the treatment period.

Age: 18Years +All GendersPhase 3
56 locations
S

Actively Recruiting

Researchers are evaluating the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of the study drug BCD-261 in patients with moderate to severe active Crohns Disease. This study involves adult men and women aged 18 to 75 years who have had an inadequate response to previous treatments such as glucocorticoids, immunosuppressants, or biologics. The trial is designed to better understand the dose-response relationship of BCD-261 compared to a placebo in this patient group. Participants are randomly assigned to one of five groups receiving different dosing regimens of BCD-261 or placebo. Four groups receive varying doses of BCD-261 low, medium, high during induction weeks 0-12 and maintenance phases, with some groups transitioning between doses. The fifth group receives placebo until the primary endpoint assessment at week 14, after which they switch to the medium dose of BCD-261. During the study, participants will be closely monitored for clinical remission and endoscopic response at week 14, with additional remission assessments at week 24. The study includes comprehensive evaluations such as safety monitoring and pharmacokinetic and pharmacodynamic assessments. Participants will be involved throughout the induction and maintenance periods with scheduled visits and assessments to track treatment effects and safety over time.

Age: 18Years - 75YearsAll GendersPhase 2
20 locations
P

Actively Recruiting

Researchers are evaluating Raphamin in adults aged 18 to 64 years who have acute bronchitis symptoms lasting less than 72 hours. This randomized, double-blind, placebo-controlled phase 3 trial aims to determine if Raphamin can speed up symptom resolution, reduce disease severity, and prevent complications requiring antibiotics compared to placebo. The study includes both men and women during the seasonal period of acute respiratory viral infections. Participants are randomly assigned to receive either Raphamin or a placebo following a specific oral dosing schedule for 5 days. On the first day, participants take 8 tablets of Raphamin or placebo one tablet every 30 minutes for the first 2 hours total of 5 tablets, then one tablet three times spaced evenly throughout the day. From day 2 onwards, one tablet is taken three times daily. The study uses an electronic patient diary to record daily symptoms, and face-to-face visits are scheduled on days 1, 4, and 7, with a phone visit on day 14. Throughout the study, participants undergo physical exams, vital sign monitoring, pulse oximetry, and laboratory tests including blood counts and PCR for respiratory viruses. Symptom severity is assessed by the Bronchitis Severity Scale and the Integrative Medicine Outcome Scale. Quality of life is evaluated using the EQ-5D instrument. Safety is monitored through recording adverse events and any use of antibacterial medications or hospitalizations. The total duration of participation includes treatment and follow-up over 14 days.

Age: 18Years - 64YearsAll GendersPhase 3
33 locations
R

Actively Recruiting

Researchers are observing adults with Chronic Rhinosinusitis With Nasal Polyps CRSwNP, with or without asthma, who have recently started treatment with tezepelumab. This observational study collects data from real-world clinical settings in Russia to understand how tezepelumab is used and its effects outside of controlled trials. The study includes about 110 adults treated according to their doctors prescriptions. Participants have initiated tezepelumab treatment no more than 4 weeks before joining the study. This non-interventional study gathers information from medical records and primary data over a year, focusing on changes in nasal polyp status and nasal congestion. The study is conducted at approximately 10 sites, following patients for up to 52 weeks after starting tezepelumab. During the study, participants medical records will be reviewed, and assessments including nasal endoscopy, nasal blockage scoring, and symptom questionnaires like SNOT-22 will be collected at baseline and at weeks 4, 24, and 52. Researchers will also evaluate healthcare use related to CRSwNP and asthma and monitor treatment duration and discontinuation. The study aims to provide comprehensive real-world data on tezepelumabs use and patient outcomes over one year.

Age: 18Years +All Genders
10 locations
O

Actively Recruiting

This trial focuses on participants with autoimmune and inflammatory conditions who have previously taken part in a Novartis study involving secukinumab. It aims to evaluate the long-term safety of secukinumab in those who continue to benefit from the treatment but cannot access the marketed version. The study is a Phase 4, open-label extension designed to provide ongoing assessment of this medication. Participants will receive secukinumab injections under the skin at doses of 75 mg, 150 mg, or 300 mg every four weeks, depending on their previous treatment dose in the parent trial. Pediatric dosing will be limited according to weight categories and prior evaluated maximum doses. Investigators can adjust doses based on clinical needs and health authority guidance. This study involves a single group receiving secukinumab with no placebo or comparator. During the study, participants will be monitored for up to two years to assess the occurrence of any adverse or serious adverse events. The trial will involve regular evaluations to track the participants safety while continuing secukinumab treatment. The total duration for participation can extend until the study ends in 2030, with ongoing safety assessments throughout this period.

Age: 6Years - 100YearsAll GendersPhase 4
171 locations
E

Actively Recruiting

Researchers are evaluating the recombinant non-immunogenic staphylokinase in patients who have suffered an acute ischemic stroke within 4.5 to 24 hours after symptom onset. This phase III, multicenter, double-blind, randomized, placebo-controlled trial focuses on patients with large vessel occlusion in the anterior circulation and salvageable brain tissue. The study aims to determine if this treatment is effective and safe when given beyond the currently recommended 4.5-hour window for intravenous thrombolysis. Participants will be randomly assigned to receive either a single intravenous bolus of 10 mg non-immunogenic staphylokinase or a placebo injection immediately after randomization. The bolus is administered rapidly within 5 to 10 seconds and is not adjusted by body weight. Patients intended for direct thrombectomy are excluded. The study includes a follow-up period of 90 days to assess outcomes. During the trial, participants will undergo neuroimaging assessments such as CT or MRI to confirm eligibility and monitor brain perfusion. Researchers will measure functional outcomes using scales like the modified Rankin scale and NIH Stroke Scale at various time points up to 90 days. They will also monitor reperfusion rates, mortality, and any adverse events. This comprehensive evaluation will help assess the treatments impact on restoring blood flow and improving recovery after stroke.

Age: 18Years +All GendersPhase 3
17 locations
S

Actively Recruiting

Researchers are evaluating the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of BCD-261, a study drug, in adults aged 18 to 75 years with moderate to severe active ulcerative colitis who have not responded adequately to previous treatments such as glucocorticoids, immunosuppressants, or biologics. This Phase 2 randomized, double-blind, placebo-controlled study aims to understand the dose-response relationship of BCD-261 in this patient population. Participants will be randomly assigned to one of five groups to receive different doses of BCD-261 or placebo. Four groups receive varied doses of BCD-261low, medium, or highduring an induction period once every 4 weeks until Week 12 followed by a maintenance period once every 8 weeks from Week 20 to Week 100 with adjusted doses. The placebo group receives injections at Weeks 0, 4, 8, and 12, then switches to BCD-261 medium dose injections every 4 weeks until Week 28, followed by a low dose every 8 weeks until Week 100. During the study, participants will be monitored regularly with assessments at specific weeks, including evaluating clinical remission at Week 14 as the primary outcome. Additional measurements at Week 24 and ongoing safety monitoring will be performed. The study involves injections, regular follow-up visits, and evaluations of disease activity, safety, and drug effects over nearly two years to gather comprehensive data on BCD-261s impact in ulcerative colitis.

Age: 18Years - 75YearsAll GendersPhase 2
20 locations
S

Actively Recruiting

Researchers are evaluating the efficacy and safety of Raphamin in treating acute rhinosinusitis in adult patients aged 18 to 75 years. This multicenter, double-blind, placebo-controlled, randomized clinical trial focuses on adults experiencing symptoms within 48 hours of disease onset during the seasonal peak of acute respiratory viral infections. The study aims to compare Raphamin against placebo in improving symptoms and quality of life. Participants will be randomly assigned to one of two groups at the first visit. One group receives Raphamin tablets dissolved in the mouth following a specific dosing schedule over 5 days, starting with multiple doses on day 1 and three times daily thereafter. The other group receives a placebo on the same schedule. The study includes a treatment period of 5 days and follow-up visits up to 14 days. Participants will attend three visits on days 1, 4, and 7, either at a medical center or at home, with a phone visit on day 14. They will complete symptom severity scales and quality of life questionnaires, record daily temperature and symptoms in an electronic diary, and report any worsening condition or adverse events. Researchers will monitor symptom improvement, safety, antibiotic use, hospitalizations, and vital signs throughout the study and follow-up period.

Age: 18Years - 75YearsAll GendersPhase 3
44 locations